Researchers have identified plectin as a biomarker for circulating tumor cells in portal and peripheral blood samples and found plectin-positive circulating tumor cells in 43.8% and 50% of portal and peripheral blood samples, respectively. This evidence concerns the gene PLEC and neoplasm.